Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-992-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated oral toxicity: non toxic
Repeated dermal toxicity: non toxic
Repeated inhalatory toxicity: no data available
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral repeated dose toxicity
A 28 days Japanese test similar to OECD 407 on BPS revealed effects at 200 mg/kg bw/day.1 2
In a repeated-dose oral study on rats, effects at the 200 mg/kg bw/day included decreased body weight gain in females, increased incidences of proteinuria in males and females and urobilinogen in males, increasing kidney weight in males, and increasing incidences of hyperplasia and necrosis in cecal mucosal epithelium of males and females (LOAEL = 200 mg/kg bw/day).3
The definitive classification of BPS as a kidney toxicant (STOT- repeated dose (Cat. 2 H371/R48) based on EU and GHS standards is not possible, therefore, a full evaluation of the toxicity of BPS was proposed by the registrant, and an OECD Guideline 408 test (Repeated Dose 90-Day Oral Toxicity in Rodents) has been completed. In this recent repeated dose 90 -Day oral toxicity study in rodents (2014), the NOAEL for male rats was determined to be 100 mg/kg bw/day (nominal) based on relative body weight and atrophy of mammary gland effects while the NOAEL for female rats was determined to be 300 mg/kg bw/day (nominal) based on the following effects: regenerative anaemia, effects on liver (hypertrophy), uterus (epithelial metaplasia) and ovaries (relative weights). Based on these data, BPS is not considered a repeated dose toxicant.
2,4'-sulfonyldiphenol CAS 5397-34-2 is considered non toxic for the repeated oral dose toxicity, and no data are available.
Also, data on benzenesulfonic acid, 4-hydroxy-, sodium salt (1:1), CAS 825-90-1 is not available.
The substance is the salified form of phenol sulfonic acid, which is a very acidic substance (comparable to sulphuric acid) and is almost completely ionised in watery environments, even at low pH. In fact, taking into consideration its corrosive nature, studies would cause unnecessary harm to laboratory animals. Moreover, because of the high polarity and high water solubility, the substance would be expected to be absorbed into systemic circulation to a minimal extent. For these reasons, the 28-day study will not be performed.4
Thus, more realistic data on salified similar substances called hydrotropes, can be considered.
There are a total of 6 oral repeated dose studies for the hydrotrope sodium xylenesulphonate. Toxicological properties of this substance can be helpful (in read across as well) to understand the toxicity of sodium sulphonated phenols, part of the intermediate DCB. The key study is a 90 -day oral study, conducted in 1968 and is generally comparable to the OECD 408 guideline study. In that study, the highest dose for female rats 4092 mg active ingredient (a.i.) per kilogram body weight - resulted in a loss in relative weight of the spleen. The 2nd highest dose for females - 763 mg a.i. per kilogram body weight - had no measureable adverse effects and therefore, establishes the repeat dose oral NOAEL for the test substance. The highest oral dose for male rats - 3534 mg a.i. per kilogram body weight - had no measurable adverse effects. No adverse effects were reported in a 90 day mouse study with the same substance.5Several studies on phenol are available, and the substance is already classified as STOT RE (category 2, H373) in the Index VI of CLP Regulation 1272/2008/EC. 6 7
Phenol is toxic for the repeated dose oral exposure, however it is present at 1.8%, concentration that do not add a repeated toxicity property to the whole mixture.
Dermal repeated dose toxicity
Considering the whole mixture of intermediate DCB, the sulfonic groups tend to bind tightly to proteins and carbohydrates of skin and part of the mixture has a big molecular dimension (tri-hydroxy).
Regarding the dermal hazard of BPS, it is less absorbed through the skin.
The estimated Kp of BPS is 0.000767 cm/hr and this value suggests that it could be less skin absorbed (EPI Suite v. 4.11).
2,4'-sulfonyldiphenol CAS 5397 -34-2 is considered non toxic for the repeated oral dose toxicity, and no data are available.
Also, data on benzenesulfonic acid, 4-hydroxy-, sodium salt (1:1), CAS 825-90-1 is not available.
The substance is the salified form of phenol sulfonic acid, which is a very acidic substance (comparable to sulphuric acid) and is almost completely ionised in watery environments, even at low pH. Taking into consideration its corrosive nature, studies would cause unnecessary harm to laboratory animals. Moreover, because of the high polarity and the water solubility, the substance would be expected to be absorbed into systemic circulation to a minimal extent. For these reasons, the 28-day study will not be performed.4
Thus, more realistic data on salified similar substances called hydrotropes, can be considered.
A category approach evaluation is available on sodium xylenesulphonate. The estimated toxicological property of this substance can be helpful (in read across as well) to understand the toxicity of sodium sulphonated phenols, part of the intermediate DCB.
This category approach defined it has no concern for the repeated dermal exposure.5
No data on phenol are available but it is considered non toxic for dermal repeated exposure.5
Inhalation repeated dose toxicity
No data is available on BPS, 2,4'-sulfonyldiphenol and related hydrotropes regarding the repeated inhalation toxicity.
References:
1ECHA Registration Dossier BPS CAS 80-09-1;
2SIDS INITIAL ASSESSMENT PROFILE, CAS 80-09-1, CoCAM 4, 16-18 April 2013;
3EPA, U.S. Environmental Protection Agency, Bisphenol A alternatives in thermal paper, Final Report, January 2014;
4HPV Assessment Report On Hydroxybenzenesulphonic acid CAS No. 1333-39-7, 2004, NOTOX;
5ECHA Registration Dossier, Sodium xylenesulphonate, CAS 1300 -72-7; ECHA Registration Dossier, Toluene sulphonic acid, CAS 104 -15 -4;
6Toxicological review of phenol. EPA, IRIS, 2002, EPA/635/R-02/006;
7 Bioassay of phenol for possible carcinogenicity. Report of the National Cancer Institute, n. 203, NTP 80-15, 1980.
Justification for classification or non-classification
Repeated dose toxicity
In order to classify the whole mixture for repeated toxicity, the available classification and the results of the reported studies of every known component has been taken into account.
4,4'-sulfonyldiphenol (BPS): non classified. Based on the NOAELs in male and female rats (2014) equal to 100 and 300 mg/kg bw respectively, BPS is not classified for repeated dose toxicity according to CLP Regulation EC n. 1272 of 2008, Annex I, Part 3, Table 3.9.3.
Benzenesulfonic acid, 4-hydroxy-, sodium salt (1:1)- hydrotropes, sodium xylenesulphonate (category approach): non classified
2,4'-sulfonyldiphenol: non classified (C&L ECHA inventory)
Phenol: H373 , no target organ indicated
Approximately 48% of the organic part of the intermediate under registration is composed by BPS.
Approximately 14% of the organic part of the mixture is the salified form of the phenol sulfonic acid (p-APS), benzenesulfonic acid, 4-hydroxy-, sodium salt (1:1). A category approach based on the hydrotropes can be taken into account for the classification of the whole intermediate mixture DCB. In fact, the properties of the salified form can be covered in read across with sodium xylenesulphonate (data available).
2,4'-sulfonyldiphenol is present at ca. 6%.
Phenol is present in a low concentration (1.8%) and for the evaluation of the repeated toxicity the presence >= 10 % shall be taken into account.
According to the CLP Regulation 1272/2008/EC, 3.9 section, point 3.9.3.4, Table 3.9.4, generic concentration limits shall be used to determine if the mixture is considered to be or not a repeated dose toxicant, oral or dermal.
Based on the information available, the intermediate DCB 58% is not classified as repeated dose toxicant.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.